Ångstrom Pharmaceuticals Report issue

For profit Phase 2
Founded: Solana Beach CA United States (1996)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2004
NCT00083928
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

urokinase-derived peptide (1 trial)

urokinase-derived peptide a6 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2